GH Research plc GHRS
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
GH Research plc is a clinical-stage biopharmaceutical company dedicated to transforming treatments for psychiatric and neurological disorders. It specializes in developing novel, proprietary mebufotenin (5-methoxy-N,N-dimethyltryptamine, or 5-MeO-DMT) product candidates, with GH001 as its lead pulmonary inhalation form…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryIreland
Employees73
TickerGHRS
Statistics
Market Cap$1.31B
Revenue (TTM)—
Net Income—
Net Margin—
EPS—
P/E-27.54
P/S—
P/B4.87
EV/EBITDA-15.24
ROE-19.7%
Dividend Yield—
Price$21.11
Data: Twelve Data · Revenue = mcap / P/S